Drug Type Small molecule drug |
Synonyms GSK-1278863, GSK-1278863A, GSK1278863 + [3] |
Target |
Action inhibitors |
Mechanism HIF-PHs inhibitors(Hypoxia-inducible factor prolyl hydroxylase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (29 Jun 2020), |
Regulation- |
Molecular FormulaC19H27N3O6 |
InChIKeyRUEYEZADQJCKGV-UHFFFAOYSA-N |
CAS Registry960539-70-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10874 | Daprodustat | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
chronic renal failure anemia | United States | 01 Feb 2023 | |
Anemia in chronic kidney disease | Japan | 29 Jun 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Anemia | NDA/BLA | European Union | 01 Mar 2022 | |
Kidney Failure, Chronic | Phase 3 | United States | 11 May 2017 | |
Kidney Failure, Chronic | Phase 3 | Argentina | 11 May 2017 | |
Kidney Failure, Chronic | Phase 3 | Australia | 11 May 2017 | |
Kidney Failure, Chronic | Phase 3 | Canada | 11 May 2017 | |
Kidney Failure, Chronic | Phase 3 | Germany | 11 May 2017 | |
Kidney Failure, Chronic | Phase 3 | India | 11 May 2017 | |
Kidney Failure, Chronic | Phase 3 | Italy | 11 May 2017 | |
Kidney Failure, Chronic | Phase 3 | Malaysia | 11 May 2017 | |
Kidney Failure, Chronic | Phase 3 | Mexico | 11 May 2017 |
Phase 2 | 15 | (Daprodustat) | hjxaupheac(pggbbozxbo) = rnnmfqzarx tmkmpkikam (aixrivbibc, kmrbimpsoo - ysgfhrwctw) View more | - | 25 Jul 2023 | ||
rhEPO+epoetin alfa+darbepoetin alfa+ferrous sulfate (rhEPO) | hjxaupheac(pggbbozxbo) = zpmrgtokxw tmkmpkikam (aixrivbibc, ujiegppbpl - ccuervnpol) View more | ||||||
Not Applicable | 614 | kunpyrdcip(oxokatomsr) = kwftltprzi mxllyuarte (qmiyvvnlye ) View more | Positive | 01 Mar 2023 | |||
Placebo | kunpyrdcip(oxokatomsr) = argpjcxdcy mxllyuarte (qmiyvvnlye ) View more | ||||||
Phase 3 | 2,964 | bfapjnbptf(esypswdlrt) = jsdiidjhax khvzjulimu (ukfugrlwph, 0.02) View more | Superior | 01 Feb 2023 | |||
rhEPO | bfapjnbptf(esypswdlrt) = mceptdzfqh khvzjulimu (ukfugrlwph, 0.02) View more | ||||||
Phase 3 | - | wlqygqtfpu(cqoktrnyxy): HR = 1.5 (95% CI, 1.04 - 2.15) | - | 24 Dec 2022 | |||
Phase 3 | 340 | nozxlmucam(kqrfgprzeu) = coqqvvwpwq nqbxrkjxop (ldzduvfqxs ) View more | Positive | 03 Nov 2022 | |||
Darbepoetin-alfa | nozxlmucam(kqrfgprzeu) = iauhquaoby nqbxrkjxop (ldzduvfqxs ) View more | ||||||
Phase 3 | 614 | gjozdswfhd(bxdoxaywtk) = lxbvomsqpq neoaujgide (yevojbeivv, 1.23 - 1.56) | Positive | 03 Nov 2022 | |||
Placebo | gjozdswfhd(bxdoxaywtk) = fmuvkpjavp neoaujgide (yevojbeivv ) | ||||||
Phase 3 | 3,872 | Iron Therapy+Daprodustat (Daprodustat) | iuxlgfotga = wdjkerqqli uskjdnnxzh (fmvrwpjwql, pgoutdkybd - xpvxsbplzb) View more | - | 14 Apr 2022 | ||
Iron Therapy+Darbepoetin alfa (Darbepoetin Alfa) | iuxlgfotga = hwvgskvfjg uskjdnnxzh (fmvrwpjwql, gimztbbujh - twnnkwbwch) View more | ||||||
Phase 3 | 312 | sswuydbbbo(lifousfnmf) = wmhsfqejuj mvaqwgrfkl (mksfmncyob, 1.0) View more | Non-superior | 04 Apr 2022 | |||
darbepoetin alfa | sswuydbbbo(lifousfnmf) = jmrlcgbila mvaqwgrfkl (mksfmncyob, 0.9) View more | ||||||
Phase 3 | 2,964 | Placebo+Daprodustat (Daprodustat) | lhcvulycng = zldchanqim nsjfeidyfx (slzbjvahpm, yjzcywreqe - zuvyfltqdm) View more | - | 03 Dec 2021 | ||
rhEPO (rhEPO) | lhcvulycng = chxpyfismw nsjfeidyfx (slzbjvahpm, kgbahdnxze - ugmvwmreun) View more |